Intervention

MammaPrint

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions2

Lead sponsors shown3

Clinical trials

3 shown

PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS RateNCT03900637 · 2019-11-08

ACTIVE_NOT_RECRUITING

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)NCT02269813 · 2015-04-01

COMPLETED

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence ScoreNCT01617954 · 2012-05-01

COMPLETED

Common conditions

Breast Cancer2 Hormone Receptor Positive Malignant Neoplasm of Breast1

Leading sponsors

Agendia 1 Seoul National University Hospital 1 Women's Cancer Study Group GmbH 1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.